Evidence map›Paper›PMID 38949746›Full record

ArticleDrug delivery and translational research2025

Transdermal delivery of resveratrol loaded solid lipid nanoparticle as a microneedle patch: a novel approach for the treatment of Parkinson's disease.

Akshay Bandiwadekar, Jobin Jose, Gopika Gopan, Varsha Augustin, Harsha Ashtekar, Kartik Bhairu Khot

Abstract read
PubMed Publisher
In one paragraph

Article in Drug delivery and translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Plants, Pills, and the Brain: Exploring Phytochemicals and Neurological Medicines.International journal of plant, animal and environmental sciences · 2025
    Article
  11. Wine, Polyphenols, and the Matrix Effect: Is Alcohol Always the Same?International journal of molecular sciences · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Akshay BandiwadekarNGSM Institute of Pharmaceutical Sciences, Department of Pharmaceutics,, NITTE Deemed-to-be University, Mangalore, 575018, India.
Jobin JoseNGSM Institute of Pharmaceutical Sciences, Department of Pharmaceutics,, NITTE Deemed-to-be University, Mangalore, 575018, India. jjmattam07@gmail.com.ORCID 0000-0002-2815-5384
Gopika GopanNGSM Institute of Pharmaceutical Sciences, Department of Pharmaceutics,, NITTE Deemed-to-be University, Mangalore, 575018, India.
Varsha AugustinNGSM Institute of Pharmaceutical Sciences, NITTE Deemed-to-be University, Department of NITTE University Center for Animal Research & Experimentation (NUCARE), Mangalore, 575018, India.
Harsha AshtekarNGSM Institute of Pharmaceutical Sciences, Department of Pharmacology, NITTE Deemed-to-be University, Mangalore, 575018, India.
Kartik Bhairu KhotNGSM Institute of Pharmaceutical Sciences, Department of Pharmaceutics,, NITTE Deemed-to-be University, Mangalore, 575018, India.

Funding

NITTE University NUFR2/2019-20/5
6 · The paper itself

Abstract

Parkinson's disease (PD), affecting millions of people worldwide and expected to impact 10 million by 2030, manifests a spectrum of motor and non-motor symptoms linked to the decline of dopaminergic neurons. Current therapies manage PD symptoms but lack efficacy in slowing disease progression, emphasizing the urgency for more effective treatments. Resveratrol (RSV), recognized for its neuroprotective and antioxidative properties, encounters challenges in clinical use for PD due to limited bioavailability. Researchers have investigated lipid-based nanoformulations, specifically solid lipid nanoparticles (SLNs), to enhance RSV stability. Oral drug delivery via SLNs faces obstacles, prompting exploration into transdermal delivery using SLNs integrated with microneedles (MNs) for improved patient compliance. In this study, an RSV-loaded SLNs (RSV -SLNs) incorporated into the MN patch was developed for transdermal RSV delivery to improve its stability and patient compliance. Characterization studies demonstrated favorable physical properties of SLNs with a sustained drug release profile of 78.36 ± 0.74%. The developed MNs exhibited mechanical robustness and skin penetration capabilities. Ex vivo permeation studies displayed substantial drug permeation of 68.39 ± 1.4% through the skin. In an in vivo pharmacokinetic study, the RSV-SLNs delivered through MNs exhibited a significant increase in C

Indexed as

Antiparkinson AgentsLipidsNanoparticlesParkinson DiseaseResveratrolAdministration, CutaneousAnimalsAntioxidantsDrug Delivery SystemsDrug LiberationMaleNeedlesRatsRats, Sprague-DawleySkin AbsorptionTransdermal PatchAntioxidantsAntiparkinson AgentsLipidsResveratrolMicroneedlesParkinson’s diseaseResveratrolSolid lipid nanoparticles

Identifiers

PMID38949746

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.